CION Ameerpet
BIA-ALCL is a rare T-cell lymphoma that grows in the fluid and scar-tissue capsule around a breast implant — not a breast cancer. When found early, it is very often curable. This guide explains the signs, the diagnosis and how CION's lymphoma team plans care.
Breast implant-associated anaplastic large cell lymphoma — BIA-ALCL, often searched for as "breast implant lymphoma" or "breast implant anaplastic large cell lymphoma" — is a rare type of T-cell lymphoma. It develops in the fluid and the scar-tissue capsule that the body forms around a breast implant. It is important to understand from the outset that this is a lymphoma of the immune system, not a cancer of the breast tissue and not breast cancer.
BIA-ALCL sits within the wider anaplastic large cell lymphoma family and, like the others, its cells are typically CD30-positive. Unlike systemic ALCL, however, it arises in a very specific place — around a breast implant — and most reported cases have involved a textured-surface implant. The overall risk is low, and the outlook is generally favourable when the condition is caught early.
This guide explains the symptoms to watch for, how BIA-ALCL is diagnosed and treated, and how it differs from other lymphomas. For the full picture of lymphoma care, see our Lymphoma hub and our Lymphoma Treatment in Hyderabad page. If you are worried about a change around an implant, you can Book Free Consultation with our team.
BIA-ALCL is recognised as a distinct entity in the World Health Organization classification of lymphoid tumours, and almost all reported cases have occurred in people who have had a textured-surface breast implant. The condition most often appears as a fluid collection around the implant roughly 8 to 10 years after it was placed. Because it is a lymphoma of the immune system rather than a breast cancer, it is diagnosed and managed by lymphoma specialists. (Source: WHO classification of haematolymphoid tumours, as referenced in NCCN and ESMO lymphoma guidelines.)
BIA-ALCL almost always develops years after a breast implant is placed. The classic warning sign is a persistent, late change around one breast. Watch for:
Most of these signs have ordinary, benign causes — but a breast that changes size or fills with fluid years after an implant should always be checked with an ultrasound. If fluid is found, it should be drained and tested rather than simply watched. Talk to a CION lymphoma specialist if you notice a late change around an implant.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Noticed late swelling around a breast implant, or want to understand a suspected BIA-ALCL before deciding on surgery? CION's lymphoma team is here to help.
Diagnosing BIA-ALCL correctly matters because it is easy to mistake late fluid around an implant for a routine, benign seroma. CION delivers the imaging review, fluid analysis coordination and pathology review directly, and every case goes through a multidisciplinary lymphoma tumour board.
Imaging is the first step. An ultrasound quickly shows whether there is fluid or a mass around the implant, and MRI gives more detail on the capsule and any spread. Imaging cannot confirm the diagnosis on its own, but it tells the team whether fluid needs to be sampled.
If fluid is present, it is drained and sent for specialised testing. BIA-ALCL cells are characteristically CD30-positive and ALK-negative, so CD30 immunohistochemistry and flow cytometry on the fluid are central to the diagnosis. This is not something a routine cytology report always looks for — it must be specifically requested, which is why an experienced haematopathologist is essential.
Once BIA-ALCL is confirmed, imaging (often PET-CT) is used to check whether the disease is confined to the fluid and capsule or has formed a mass or spread. This stage is the single most important factor in deciding how much treatment is needed. Per NCCN and ESMO guidance, staging should be completed before the plan is finalised.
The treatment plan depends on the stage — whether the lymphoma is confined to the fluid and capsule, or has spread beyond it. Every case is reviewed by CION's multidisciplinary tumour board before the plan is set. The main building blocks are:
For disease confined to the fluid and capsule, the primary treatment is surgery to remove the implant together with the surrounding capsule as a single specimen (en bloc capsulectomy). When this is done completely for early-stage disease, it is frequently curative on its own. CION coordinates the surgical step with an experienced surgical team; the diagnosis, staging, pathology review and any follow-on care are managed directly by our lymphoma specialists.
If the lymphoma has formed a mass or spread beyond the capsule, systemic treatment is added. This may include chemotherapy and, in selected cases, an anti-CD30 antibody-based therapy that targets the CD30 marker on the lymphoma cells. CION's medical oncology team delivers these systemic treatments directly. Specific regimen names and dosing are individual to each patient and are decided by your treating team — see our Lymphoma Treatment in Hyderabad page for how plans are built.
For some cases where disease is not fully removed or has features that warrant it, precision radiation therapy (IMRT) may be used, delivered by CION directly. The role of radiation is decided case by case at the tumour board.
After treatment, follow-up focuses on confirming the response and watching for any recurrence, alongside supportive and survivorship care managed in-house. If you are researching your options, our best lymphoma doctors in Hyderabad and best lymphoma hospital in Hyderabad pages explain the team and facilities behind this care.
When BIA-ALCL is confined to the fluid or capsule around the implant and is completely removed by surgery, the outlook is very favourable and complete removal alone is often curative. To put lymphoma outcomes in context more broadly, published series report survival of roughly 80–90% for Hodgkin lymphoma and around 60–70% for diffuse large B-cell lymphoma — though these are different diseases and figures always vary by individual, stage and general health. (Sources: NCCN and ESMO lymphoma guidelines and published outcome series.)
BIA-ALCL is one member of a larger group. Understanding the related subtypes helps explain why its treatment is so different — its local, implant-associated origin means surgery plays a central role that it does not play in the nodal or skin lymphomas.
The broader ALCL family. All are CD30-positive, but systemic (nodal) ALCL arises in lymph nodes and is treated with systemic therapy first, unlike the surgery-led approach for early BIA-ALCL.
The wider category that BIA-ALCL belongs to. T-cell lymphomas begin in T-lymphocytes and behave very differently from the more common B-cell lymphomas.
A group of mostly nodal T-cell lymphomas. Reviewing the related subtypes can help when a pathology report is being interpreted.
A T-cell lymphoma that begins in the skin (mycosis fungoides). Included here to show the range of sites T-cell lymphomas can start from.
Because BIA-ALCL is rare and easily overlooked, a second opinion is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if fluid around your implant has not yet been tested for CD30.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.BIA-ALCL is a rare type of T-cell lymphoma that develops in the scar-tissue capsule and fluid surrounding a breast implant. It is not a cancer of the breast tissue itself and it is not breast cancer — it is a lymphoma of the immune system. Sometimes searched for as "breast implant lymphoma" or "breast implant anaplastic large cell lymphoma", BIA-ALCL is a distinct entity within the anaplastic large cell lymphoma family. Most cases are linked to textured-surface implants. When found early and confined to the fluid or capsule, it is very often curable with surgery to remove the implant and the surrounding capsule.
The most common sign is persistent swelling or fluid build-up around one breast implant, usually appearing years after the implant was placed — on average 8 to 10 years later. This fluid collection (a seroma) can make the breast feel larger, firm or asymmetric. Less commonly, a lump in the breast or armpit, skin changes, or capsular hardening (contracture) may occur. Because these signs can also have benign causes, any new, late-onset swelling around an implant should be assessed promptly with an ultrasound and, if fluid is found, testing of that fluid. Do not ignore a breast that suddenly changes size long after surgery.
Nearly all reported cases of BIA-ALCL have occurred in people who have had a textured-surface implant at some point — either for cosmetic augmentation or for reconstruction after breast cancer surgery. The risk has not been clearly linked to smooth-surface implants alone. The overall lifetime risk is low, but it is not zero, which is why regulators and surgical societies advise awareness rather than alarm. If you have textured implants and no symptoms, routine removal is generally not recommended. If you are unsure what type of implant you have, your original operative records or implant card will state the make and surface.
Diagnosis starts with an ultrasound or MRI to look for fluid or a mass around the implant. If fluid is present, it is drained and sent for specialised testing — cytology plus CD30 immunohistochemistry and flow cytometry, because BIA-ALCL cells are characteristically CD30-positive and ALK-negative. If a capsule mass is suspected, tissue is examined too. Confirming the diagnosis needs a haematopathologist experienced in lymphoma, not a routine breast biopsy. At CION, our team coordinates the fluid analysis and CD30 testing and reviews every case at a multidisciplinary lymphoma tumour board before any treatment plan is set.
For disease confined to the fluid and the capsule, the primary treatment is surgery — complete removal of the implant together with the surrounding scar-tissue capsule (en bloc capsulectomy), coordinated with an experienced surgical team. When done completely for early disease, this alone is often curative. If the lymphoma has spread beyond the capsule or formed a mass, systemic treatment such as chemotherapy — and in selected cases an anti-CD30 antibody-based therapy — may be added, delivered by CION directly. Radiation is used in some cases. Regimen names and dosing are individual to each patient; see our Lymphoma Treatment in Hyderabad page for how plans are built.
The outlook for BIA-ALCL is generally favourable, especially when it is found early and is limited to the fluid or capsule around the implant. In those cases, complete surgical removal of the implant and capsule alone is frequently curative, and published series report high survival. The outlook is less certain when the disease has spread beyond the capsule as a mass, which is why early assessment of any late swelling matters. According to NCCN and ESMO guidance, staging with imaging guides how much treatment is needed. Figures vary by individual, so your own stage, extent and general health shape your specific prognosis — discuss this with your specialist.
BIA-ALCL belongs to the anaplastic large cell lymphoma family but is recognised as its own distinct entity. Like other ALCLs it is CD30-positive, but BIA-ALCL is ALK-negative and, crucially, arises in a very specific setting — the capsule and fluid around a breast implant — rather than in lymph nodes or skin. This local, implant-associated origin means that surgery to remove the implant and capsule plays a central, often curative role, which is not the case for systemic nodal ALCL. Both sit within the broader group of T-cell lymphomas, and both are managed under NCCN and ESMO lymphoma frameworks.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.